Status:
RECRUITING
Metformin in Safety and Efficacy in Gouty Patients
Lead Sponsor:
Mostafa Bahaa
Conditions:
Gout
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is ...
Eligibility Criteria
Inclusion
- Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.
Exclusion
- Systemic disorders such as cardiovascular, neurological, coronary artery disease.
- Hypertension, hyperlipidemia, diabetes mellitus, active infections.
- Other inflammatory or autoimmune diseases.
- Patients on biologics,
- Cases with hypersensitivity to metformin and those with impaired liver and kidney functions.
Key Trial Info
Start Date :
April 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 20 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06924658
Start Date
April 20 2025
End Date
November 20 2026
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta Unuversity
Tanta, Egypt, 31527